Valerian for Sleep Quality

Sleep Quality — scientific infographic poster

Valerian is the most-popular herbal sleep aid in the Western world and one of the most heavily studied. The clinical evidence base contains more than two dozen randomized controlled trials, four published systematic reviews, and one widely-cited meta-analysis (Bent 2006) that pooled 16 trials. Its headline conclusion was that "the available evidence suggests that valerian might improve sleep quality without producing side effects", while noting that most studies had significant methodologic problems. A common explanation for the mixed results is that valerian fails as a first-night hypnotic but works after two to four weeks of nightly use, as one 2000 sleep-laboratory trial suggested. Later and more rigorous trials did not confirm this: a 2007 systematic review titled "safe but not effective" found most studies showed no difference from placebo, a 2009 trial of two weeks of nightly use found no effect, and a 2010 meta-analysis found no difference in measured time to fall asleep. The dose most often cited is 600-900 mg of a 0.8% valerenic acid extract (or 2-3 g of dried root), taken about an hour before bed; advocates of the chronic-use model describe at least 14 nights of use before judging it. This page walks through the pivotal trials, the proposed mechanism, the dose-response, the comparison with prescription hypnotics, and the practical facts for people considering valerian for chronic insomnia.


Table of Contents

  1. Valerian as Sleep Aid — Historical Use
  2. The Leathwood 1982 Trial (Most-Cited Paper)
  3. The Donath 2000 Sleep-Latency Crossover
  4. The Bent 2006 Meta-Analysis (16 Trials)
  5. Mechanism — Valerenic Acid, Valepotriates, GABA Transaminase, 5-HT5A
  6. The 600-900 mg Standardized Dose Range
  7. Chronic Use and the Cumulative-Effect Model
  8. Compared to Prescription Hypnotics (Benzodiazepines, Z-Drugs, Trazodone)
  9. Effect on Sleep Architecture (Polysomnographic Findings)
  10. Combination Products (Valerian + Hops, Valerian + Lemon Balm)
  11. Practical Facts for People Considering Valerian
  12. Cautions, Drug Interactions, and Failure Modes
  13. Key Research Papers
  14. Connections
  15. Featured Videos

Valerian as Sleep Aid — Historical Use

Valerian has been used as a sleep aid in European herbal medicine for at least two thousand years. The Greek physician Dioscorides (first century CE) described phou (later identified as Valeriana) in De Materia Medica as a treatment for "agitation, sleeplessness, and nervous restlessness." Galen prescribed it for insomnia. Hildegard of Bingen (twelfth century) recommended valerian root preparations for what we would now call generalized anxiety and stress-related insomnia. In the United States, valerian appeared in the United States Pharmacopeia from 1820 to 1942 as an officially-recognized sedative, and was used extensively during World War I to treat what was then called "shell shock" — a precursor to the modern diagnosis of post-traumatic stress disorder (PTSD) with prominent sleep disturbance.

Valerian was largely displaced from clinical practice in the 1950s and 1960s by the introduction of barbiturates and then benzodiazepines, which had dramatically faster onset of action and more predictable dose-response. It was rediscovered as a herbal alternative in the 1970s and 1980s, particularly in Germany, where the regulatory framework under Commission E recognized it as a traditional herbal medicinal product (THMP) for sleep disturbance and mild nervous tension. The German Commission E monograph from 1985 specifies an internal use dose of "1 cup of tea made from 2-3 g of dried herb, taken one or more times daily" for restlessness and difficulty falling asleep.

Modern Western use is dominated by standardized commercial extracts (typically 0.8% valerenic acid) marketed in capsule form at 300-600 mg per capsule, with a typical retail dose of one to three capsules at bedtime. Annual U.S. retail sales are estimated in the hundreds of millions of dollars, consistently placing valerian among the top-five-selling sleep aids by revenue.

Back to Table of Contents

The Leathwood 1982 Trial (Most-Cited Paper)

The Leathwood 1982 paper, published in Pharmacology, Biochemistry, and Behavior, is the single most-cited valerian sleep study and the modern starting point for the clinical literature. Peter Leathwood and colleagues at Nestlé Research Laboratories in Switzerland tested an aqueous extract of valerian root (400 mg) and a proprietary over-the-counter valerian preparation against placebo in 128 people. Each person received nine coded samples in random order — three placebo, three of the 400 mg extract and three of the over-the-counter preparation — taken on non-consecutive nights. Participants completed sleep questionnaires each morning rating subjective sleep latency, sleep quality, number of nocturnal awakenings, and morning grogginess.

Results:

The trial is often cited for two principles, although later and more rigorous trials did not confirm the first (see the Bent and Taibi reviews below). First, valerian's effect on sleep, even in single-dose administration, is real but modest — an effect size estimated around 0.4 on the Cohen's d scale, comparable to a low dose of a non-benzodiazepine hypnotic. Second, practitioners describe a non-linear dose-response, with the typical plateau around 400-600 mg of standardized extract, beyond which additional dose produces minimal additional sedation.

A subsequent follow-up trial by the same group (Leathwood and Chauffard 1985, Planta Medica) extended the design to objective measures by recording wrist actigraphy alongside subjective questionnaires. The actigraphy data showed reduced movement during the sleep-onset period on valerian nights, providing the first objective corroboration of the subjective sleep-latency reduction.

Back to Table of Contents

The Donath 2000 Sleep-Latency Crossover

The Donath 2000 trial (Donath F, Quispe S, Diefenbach K, Maurer A, Fietze I, Roots I., Pharmacopsychiatry) was the first valerian study to use full overnight polysomnography (PSG) rather than relying on subjective questionnaires or actigraphy alone. 16 patients with documented psychophysiological insomnia received 600 mg of a hydroalcoholic valerian extract (LI-156, the same extract used in many subsequent European trials) or matching placebo in a crossover design, with PSG monitoring across multiple study nights.

Results at the single-dose level (first night) confirmed the impression from earlier acute trials: valerian produced no significant change in objectively-measured sleep latency, total sleep time, sleep efficiency, or REM/NREM distribution on the first night of dosing. However, when the protocol was extended (a 14-day chronic-dosing arm published in the same paper), the same patients showed measurable improvements in slow-wave sleep (stage 3-4 NREM) and a reduction in sleep latency that approached statistical significance.

The Donath 2000 paper is the main source for what has come to be called the "valerian onset paradox": the idea that valerian does not work on the first night but does work after two weeks of consistent use. On that idea, a valerian trial that uses a one-night or three-night protocol would find no effect even if valerian works over weeks, because the trial design does not allow a cumulative effect to develop.

Later trials that tested valerian over weeks did not bear the idea out. A 2007 systematic review of 37 studies found that most showed no significant difference between valerian and placebo, and that none of the most recent studies — also the most methodologically rigorous — found significant effects on sleep; a 2009 randomised trial of two weeks of nightly valerian also found no effect (see the next sections).

Back to Table of Contents

The Bent 2006 Meta-Analysis (16 Trials)

The Bent et al. 2006 meta-analysis, published in the American Journal of Medicine, is the most-cited quantitative synthesis of the valerian sleep literature. The authors identified 16 randomized placebo-controlled trials of valerian for sleep (out of 370 records screened), totaling 1,093 patients across studies conducted in Germany, Switzerland, the United States, the United Kingdom, and Sweden between 1981 and 2005.

Headline findings:

The authors' overall conclusion: "The available evidence suggests that valerian might improve sleep quality without producing side effects. Future studies should assess a range of doses of standardized preparations of valerian and include standard measures of sleep quality and safety." They also reported that most of the studies had significant methodologic problems. This is the conclusion that has been most widely quoted from the literature.

A subsequent Taibi et al. 2007 systematic review (Sleep Medicine Reviews), titled "A systematic review of valerian as a sleep aid: safe but not effective", reached a more negative conclusion. Of 37 studies reviewed (29 controlled trials and 8 open-label safety studies), most found no significant differences between valerian and placebo, either in healthy people or in people with sleep disturbance or insomnia, and none of the most recent studies, which were also the most methodologically rigorous, found significant effects of valerian on sleep. The authors concluded that valerian is a safe herb associated with only rare adverse events, but that the evidence does not support its clinical efficacy as a sleep aid for insomnia.

A 2010 meta-analysis of 18 randomised placebo-controlled trials (Fernández-San-Martín and colleagues, Sleep Medicine) separated what people reported from what was measured. People on valerian were more likely to say their sleep had improved (relative risk 1.37, 95% CI 1.05 to 1.78), but the measured time to fall asleep differed from placebo by only 0.70 minutes (95% CI −3.44 to 4.83), and sleep-quality scores on rating scales did not differ. The authors concluded that valerian may give a subjective improvement in insomnia, but that its effectiveness "has not been demonstrated with quantitative or objective measurements."

A 2020 systematic review and meta-analysis (Shinjyo and colleagues) covered 60 studies with 6,894 people and pooled 10 studies (1,065 people) on subjective sleep quality. It suggested that the inconsistent results may be due to the variable quality of herbal extracts, with more reliable effects expected from the whole root and rhizome, and it found no severe adverse events in people aged 7 to 80. Its authors concluded that valerian could be a safe and effective herb to promote sleep.

The American Academy of Sleep Medicine's 2017 clinical practice guideline on medicines for chronic insomnia in adults states: “We suggest that clinicians not use valerian as a treatment for sleep onset or sleep maintenance insomnia (versus no treatment) in adults.” It is graded a WEAK recommendation, which the guideline defines as reflecting a lower degree of certainty, not as an indication of ineffectiveness.

Back to Table of Contents

Mechanism — Valerenic Acid, Valepotriates, GABA Transaminase, 5-HT5A

The pharmacology of valerian's sedative-hypnotic effect involves multiple low-affinity mechanisms acting on overlapping central nervous system (CNS) pathways, none individually sufficient to explain the clinical effect.

Valerenic acid (the lead modern actor). Valerenic acid is a sesquiterpene unique to Valeriana officinalis (not found in related V. wallichii, V. edulis, or other commercial substitutes). It is the standardization target for most modern commercial extracts. The receptor pharmacology has been characterized over the past two decades:

Valepotriates (the controversial older actor). Valepotriates are epoxide-containing iridoid esters that were originally proposed as the primary sedative principle in valerian. They have several problematic properties: they degrade rapidly on storage (so commercial dried-root preparations contain very little after a few months on the shelf), they have raised genotoxicity flags in some in vitro assays (Ames test, sister chromatid exchange), and they are absorbed poorly from the gut. Modern standardized extracts often deliberately exclude valepotriates by using aqueous or ethanol extraction methods that leave them behind. The clinical effect of these modern valepotriate-free extracts is essentially a valerenic-acid effect, which is reassuring from a safety perspective.

GABA transaminase inhibition mechanism. The GABA transaminase inhibition hypothesis is appealing because it predicts a cumulative effect: chronic inhibition of GABA transaminase should produce a gradual increase in central nervous system gamma-aminobutyric acid tone over days to weeks, paralleling the delayed onset reported in some trials (Donath 2000). This contrasts sharply with the mechanism of benzodiazepines (which directly amplify gamma-aminobutyric acid-A response and produce immediate effect) and with the mechanism of barbiturates (which open chloride channels even in absence of gamma-aminobutyric acid and again produce immediate effect). If valerian's effect is slow in onset, as the cumulative model holds, it would fit a GABA transaminase mechanism better than either of those.

The 5-HT5A binding finding. The 5-HT5A receptor is expressed primarily in the suprachiasmatic nucleus (the brain's master circadian clock), the dorsal raphe (a major serotonergic nucleus), and the cerebellum. Its function is poorly characterized, and there are essentially no other drugs that bind it selectively. The hypothesis that valerian's "different feel" compared to benzodiazepines (more dream-rich sleep, less morning cognitive impairment, less amnestic effect) may relate to 5-HT5A modulation is an active area of research but not yet established.

For the broader discussion of how multiple weak mechanisms can produce a meaningful clinical effect through additive low-affinity action, see our Valerian Benefits Hub.

Back to Table of Contents

The 600-900 mg Standardized Dose Range

The consensus dose range for modern standardized valerian extracts is 600-900 mg of a 0.8% valerenic acid extract, taken one hour before bed, every night. This range emerged from the clinical trial literature in the late 1990s and early 2000s and is reflected in the German Commission E monograph, the European Medicines Agency HMPC monograph, and most North American consumer products.

The dose-equivalents across different preparations:

Several practical considerations modify the standard guidance:

Back to Table of Contents

Chronic Use and the Cumulative-Effect Model

The cumulative-effect model holds that valerian works only after days to weeks of nightly use. Some trials fit it: the Donath 2000 trial found no single-dose effect but improvements in slow-wave sleep after multiple doses. The wider trial literature does not: the 2007 Taibi review found most studies showed no significant difference from placebo whatever their length, and the 2010 meta-analysis of 18 trials found no difference in measured time to fall asleep (0.70 minutes). If the model is right, the pattern is the opposite of the pattern with benzodiazepines and Z-drugs (immediate effect, tolerance with chronic use) and is more reminiscent of selective serotonin reuptake inhibitors (delayed onset, sustained effect with chronic use).

The most direct test of two weeks of nightly use is a 2009 randomised, double-blind crossover trial in 16 older women with insomnia (average age 69). They took 300 mg of concentrated valerian extract or placebo 30 minutes before bedtime for 2 weeks, and their sleep was measured in the sleep laboratory (by questionnaire and polysomnography) and at home (by sleep logs and wrist actigraphy). There were no statistically significant differences between valerian and placebo after a single dose or after 2 weeks of nightly dosing on any measure of time to fall asleep, time awake after first falling asleep, sleep efficiency or self-rated sleep quality. Side effects were minor and did not differ from placebo.

Three hypotheses for the cumulative effect have been proposed:

  1. Active compound accumulation — the idea that valerenic acid builds up over days of repeated dosing to a level that is too low on the first dose. The measurements do not support it: valerenic acid has a short elimination half-life (1.1 ± 0.6 hours in 6 healthy adults given 600 mg; one of the six showed a second peak at 5 hours), and in older women its peak level, total exposure and half-life did not differ significantly after 2 weeks of nightly dosing compared with a single dose.
  2. Adaptive change in gamma-aminobutyric acid-A receptor expression or function — chronic GABA transaminase inhibition (raising synaptic gamma-aminobutyric acid) may induce a homeostatic increase in post-synaptic gamma-aminobutyric acid-A receptor sensitivity or density, the opposite of the well-documented receptor downregulation seen with chronic benzodiazepine use.
  3. Anxiolytic-mediated sleep effect — valerian's primary effect may be reduction of pre-sleep anxiety and physiological hyperarousal, which itself takes 1-2 weeks of consistent use to manifest. Better sleep would then be a secondary consequence of a less hyperaroused state, not a direct hypnotic effect.

Advocates of the cumulative model hold that a personal valerian trial shorter than two weeks is not informative, and describe taking 600-900 mg every night for two to four weeks before judging whether it works; they say many people conclude "it didn't work for me" after one or two nights. The two-week randomised trial above, at 300 mg, found no difference from placebo.

For the broader insomnia context including the prescription-hypnotic alternatives and cognitive behavioral therapy for insomnia (CBT-I, the first-line treatment for chronic insomnia per the American Academy of Sleep Medicine), see our Insomnia page.

Back to Table of Contents

Compared to Prescription Hypnotics (Benzodiazepines, Z-Drugs, Trazodone)

The clinically useful comparison is not "is valerian as effective as zolpidem" (it is not) but "what is valerian useful for that prescription hypnotics are not."

Benzodiazepines (temazepam, lorazepam, clonazepam, alprazolam). Prescription benzodiazepines have an immediate, large effect on sleep latency on the first night, but they produce tolerance (loss of effect with chronic use), dependence (need for the drug to feel normal), withdrawal (rebound insomnia and anxiety on discontinuation), and substantial cognitive carry-over the next morning. Older patients on chronic benzodiazepines have measurably increased fall risk, hip fracture risk, and dementia risk. The American Geriatrics Society Beers Criteria explicitly recommends against routine benzodiazepine use in adults over 65. Valerian produces a smaller acute effect than a benzodiazepine but does not produce tolerance, dependence, or significant cognitive carry-over, which is why herbal practitioners regard it as preferable for chronic use by people who do not need maximal acute effect.

Z-drugs (zolpidem, eszopiclone, zaleplon). Z-drugs were developed to address the cognitive carry-over of benzodiazepines and have largely succeeded on that front. However, they retain tolerance and dependence concerns with chronic use, and zolpidem in particular has well-documented complex sleep behaviors (sleepwalking, sleep-eating, sleep-driving) in a minority of users. Valerian's safety profile is meaningfully better than zolpidem's for chronic use.

Trazodone. Low-dose trazodone (50-100 mg) is commonly prescribed off-label for insomnia and has a different profile from either benzodiazepines or Z-drugs: it does not produce dependence and does not lose effect with chronic use. Trazodone is probably more effective than valerian on a head-to-head comparison and is used for patients who tolerate it. The downside is the side effect profile: orthostatic hypotension, anticholinergic effects, occasional priapism in men, and morning grogginess in some patients. Valerian is gentler on all of these dimensions but less effective.

Melatonin. Melatonin is a chronobiotic rather than a true hypnotic. It works best for circadian-rhythm sleep disorders (jet lag, shift work, delayed sleep-phase syndrome) rather than primary insomnia. Some people combine melatonin with valerian when they have both a delayed sleep phase and primary insomnia.

Diphenhydramine and other over-the-counter (OTC) antihistamines. Diphenhydramine (sold alone and in night-time pain-reliever combinations) is the most commonly used over-the-counter sleep aid in the United States. It has substantial anticholinergic burden, is on the Beers Criteria for avoidance in older adults, and rapidly develops tolerance with nightly use. Herbal practitioners regard it as in most respects a worse choice than valerian for chronic over-the-counter use, though it is still used for occasional acute sleeplessness.

Herbal practitioners position valerian as an over-the-counter sleep aid for adults with chronic mild-to-moderate insomnia who want to avoid prescription hypnotics, who are willing to commit to a 14-day trial, and who are not seeking immediate first-night effect. The American Academy of Sleep Medicine's 2017 guideline, by contrast, suggests that clinicians not use valerian for trouble falling or staying asleep (a WEAK recommendation; see the review section above).

Back to Table of Contents

Effect on Sleep Architecture (Polysomnographic Findings)

The PSG studies of valerian, taken together, suggest a profile that differs from prescription hypnotics in important ways:

The pattern is consistent with valerian's reputation as a gentler agent: smaller acute effect, but more preservation of natural sleep architecture, less cognitive carry-over, and no rebound insomnia on discontinuation. Herbal practitioners present it as an option for people who put sleep architecture and morning function ahead of peak acute hypnotic effect.

Back to Table of Contents

Combination Products (Valerian + Hops, Valerian + Lemon Balm)

Several traditional and modern formulations combine valerian with other sedative herbs, on the theory that the additive low-affinity-mechanism model that explains valerian within itself also applies to combinations.

Valerian + Hops (Humulus lupulus). The valerian-plus-hops combination is the most-studied. Hops contains 2-methyl-3-buten-2-ol, which has documented sedative activity and binds to gamma-aminobutyric acid-A receptors. The Schmitz and Jäckel 1998 randomized controlled trial (RCT), a double-blind parallel-group study with no placebo arm, compared a valerian-hops combination with a low-dose benzodiazepine (bromazepam) in 46 patients with non-chronic sleep disorders (temporary trouble falling or staying asleep); over 2 weeks of treatment the combination was equivalent to the benzodiazepine on sleep quality, fitness and quality of life, and withdrawal symptoms were documented with the benzodiazepine. Several subsequent trials have replicated this favorable result, and valerian-hops combination products are widely sold in Europe under several brand names.

Valerian + Lemon Balm (Melissa officinalis). Lemon balm has documented anxiolytic and mild sedative effects mediated by inhibition of gamma-aminobutyric acid transaminase — the same mechanism as valerian, suggesting additive rather than synergistic action. The Cerny and Schmid 1999 trial (a double-blind, placebo-controlled multicentre study of tolerability and efficacy in healthy volunteers) and the Müller and Klement 2006 pediatric study are cited in support of valerian-lemon balm combinations for sleep restlessness, particularly in children. The Müller and Klement study was open, with no control group: in 918 children under 12 with restlessness and sleep problems, dosed individually by the investigators, 80.9% of those with sleep problems and 70.4% of those with restlessness were rated as improved. Its first author worked for the product's manufacturer. See our Lemon Balm page.

Valerian + Passionflower (Passiflora incarnata). Passionflower contains chrysin and other flavonoids with gamma-aminobutyric acid-A modulating activity. The combination is widely used in over-the-counter sleep formulations but has less randomized controlled trial evidence than the valerian-hops combination. See our Passionflower page.

Valerian + Magnesium. Magnesium glycinate (the most-absorbed and most-calming form) at 200-400 mg taken at bedtime alongside valerian is a widely-used combination, especially in patients with concurrent muscle tension or restless legs symptoms. The mechanisms are complementary (magnesium acts at the N-methyl-D-aspartate (NMDA) receptor and as a calcium-channel modulator, valerian at gamma-aminobutyric acid pathways). See our Magnesium Glycinate page.

Back to Table of Contents

Practical Facts for People Considering Valerian

Back to Table of Contents

Cautions, Drug Interactions, and Failure Modes

For the broader cautions discussion across all valerian benefits including the smell-tolerance issue, see the Valerian Benefits Hub.

Back to Table of Contents

Key Research Papers

  1. Leathwood PD, Chauffard F, Heck E, Munoz-Box R (1982). Aqueous extract of valerian root (Valeriana officinalis) improves sleep quality in man. Pharmacology, Biochemistry, and Behavior. — PubMed PMID: 7122669
  2. Leathwood PD, Chauffard F (1985). Aqueous extract of valerian reduces latency to fall asleep in man. Planta Medica (2):144-8. — PubMed PMID: 4034730
  3. Donath F, Quispe S, Diefenbach K, Maurer A, Fietze I, Roots I (2000). Critical evaluation of the effect of valerian extract on sleep structure and sleep quality. Pharmacopsychiatry 33(2):47-53. — PubMed PMID: 10761819
  4. Bent S, Padula A, Moore D, Patterson M, Mehling W (2006). Valerian for sleep: a systematic review and meta-analysis. American Journal of Medicine 119(12):1005-12. — PubMed PMID: 17145239
  5. Taibi DM, Landis CA, Petry H, Vitiello MV (2007). A systematic review of valerian as a sleep aid: safe but not effective. Sleep Medicine Reviews 11(3):209-30. — PubMed PMID: 17517355
  6. Taibi DM, Vitiello MV, Barsness S, Elmer GW, Anderson GD, Landis CA (2009). A randomized clinical trial of valerian fails to improve self-reported, polysomnographic, and actigraphic sleep in older women with insomnia. Sleep Medicine 10(3):319-28. — PubMed PMID: 18482867
  7. Schmitz M, Jäckel M (1998). Comparative study for assessing quality of life of patients with exogenous sleep disorders treated with a hops-valerian preparation and a benzodiazepine drug. Wiener Medizinische Wochenschrift. — PubMed PMID: 9757514
  8. Khom S, Baburin I, Timin E, et al. (2007). Valerenic acid potentiates and inhibits GABA-A receptors: molecular mechanism and subunit specificity. Neuropharmacology. — PubMed PMID: 17585957
  9. Benke D, Barberis A, Kopp S, et al. (2009). GABA-A receptors as in vivo substrate for the anxiolytic action of valerenic acid, a major constituent of valerian root extracts. Neuropharmacology. — PubMed PMID: 18602406
  10. Trauner G, Khom S, Baburin I, Benedek B, Hering S, Kopp B (2008). Modulation of GABA-A receptors by valerian extracts is related to the content of valerenic acid. Planta Medica. — PubMed PMID: 18095218
  11. Cropley M, Cave Z, Ellis J, Middleton RW (2002). Effect of kava and valerian on human physiological and psychological responses to mental stress. Phytotherapy Research. — PubMed PMID: 11807960
  12. Stevinson C, Ernst E (2000). Valerian for insomnia: a systematic review of randomized clinical trials. Sleep Medicine. — PubMed PMID: 10767649
  13. Fernández-San-Martín MI, Masa-Font R, Palacios-Soler L, Sancho-Gómez P, Calbó-Caldentey C, Flores-Mateo G (2010). Effectiveness of Valerian on insomnia: a meta-analysis of randomized placebo-controlled trials. Sleep Medicine 11(6):505-11. — PubMed PMID: 20347389
  14. Anderson GD, Elmer GW, Kantor ED, Templeton IE, Vitiello MV (2005). Pharmacokinetics of valerenic acid after administration of valerian in healthy subjects. Phytotherapy Research 19(9):801-3. — PubMed PMID: 16220575
  15. Anderson GD, Elmer GW, Taibi DM, Vitiello MV, Kantor E, Kalhorn TF, Howald WN, Barsness S, Landis CA (2010). Pharmacokinetics of valerenic acid after single and multiple doses of valerian in older women. Phytotherapy Research 24(10):1442-6. — PubMed PMID: 20878691
  16. Müller SF, Klement S (2006). A combination of valerian and lemon balm is effective in the treatment of restlessness and dyssomnia in children. Phytomedicine 13(6):383-7. — PubMed PMID: 16487692
  17. Cerny A, Schmid K (1999). Tolerability and efficacy of valerian/lemon balm in healthy volunteers (a double-blind, placebo-controlled, multicentre study). Fitoterapia 70(3):221-228. — doi:10.1016/s0367-326x(99)00018-0
  18. Shinjyo N, Waddell G, Green J (2020). Valerian Root in Treating Sleep Problems and Associated Disorders-A Systematic Review and Meta-Analysis. Journal of Evidence-Based Integrative Medicine 25:2515690X20967323. — PubMed PMID: 33086877
  19. Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL (2017). Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. Journal of Clinical Sleep Medicine 13(2):307-349. — PubMed PMID: 27998379
  20. Hadley S, Petry JJ (2003). Valerian. American Family Physician. — PubMed PMID: 12725454

PubMed Topic Searches

  1. PubMed: Valerian insomnia RCTs
  2. PubMed: Valerenic acid GABA mechanism
  3. PubMed: Valerian-hops combinations
  4. PubMed: Valerian and sleep architecture
  5. PubMed: Valerian dose-response in chronic insomnia

Back to Table of Contents

Connections

Back to Table of Contents